April 22, 2014 - 4:03 p.m.
Gilead Sciences Announces First Quarter 2014 Financial Results
Printer Friendly Version 
April 21, 2014 - 5:04 p.m.
Gilead Sciences’ New Drug Applications for Cobicistat and Elvitegravir for HIV Therapy Accepted by U.S. FDA
Printer Friendly Version 
April 15, 2014 - 5:00 p.m.
Gilead Sciences to Release First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Printer Friendly Version 
April 11, 2014 - 1:03 a.m.
Gilead’s Sovaldi® Demonstrates Efficacy and Safety Among Chronic Hepatitis C Patients with Advanced Liver Disease
Printer Friendly Version 
April 10, 2014 - 1:04 a.m.
Gilead Announces Phase 2 Results for Two Investigational All-Oral Sofosbuvir-Based Regimens for the Treatment of Chronic Hepatitis C
Printer Friendly Version 
April 10, 2014 - 1:03 a.m.
Gilead Announces Results from Study of Sovaldi® for Retreatment of Chronic Hepatitis C in Patients Not Cured with Prior Antiviral Therapy
Printer Friendly Version 
April 07, 2014 - 8:30 a.m.
Gilead Announces U.S. FDA Priority Review Designation for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Chronic Hepatitis C Genotype 1 Infection
Printer Friendly Version 
April 02, 2014 - 4:31 p.m.
Gilead Announces Results From Phase 3 Study of Sofosbuvir Among Hepatitis C Patients in Japan
Printer Friendly Version 
March 28, 2014 - 8:31 a.m.
Gilead Announces Settlement Method for 1.00% Convertible Senior Notes Due 2014
Printer Friendly Version 
March 27, 2014 - 4:11 p.m.
European Medicines Agency Validates Gilead’s Marketing Application for Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Chronic Hepatitis C Infection
Printer Friendly Version 
March 04, 2014 - 6:20 p.m.
Gilead Prices $4 Billion of Senior Unsecured Notes
Printer Friendly Version 
February 28, 2014 - 5:01 p.m.
Gilead Sciences to Present at the 34th Cowen & Co. Healthcare Conference on Monday, March 3
Printer Friendly Version 
February 25, 2014 - 5:01 p.m.
Gilead Sciences to Present at the RBC Capital Markets 2014 Global Healthcare Conference on Wednesday, February 26
Printer Friendly Version 
February 10, 2014 - 5:01 p.m.
Gilead Sciences to Present at Two Upcoming Investor Conferences
Printer Friendly Version 
February 10, 2014 - 4:06 p.m.
Gilead Files for U.S. Approval of Ledipasvir/Sofosbuvir Fixed-Dose Combination Tablet for Genotype 1 Hepatitis C
Printer Friendly Version 
February 04, 2014 - 4:06 p.m.
Gilead Sciences Announces Fourth Quarter and Full Year 2013 Financial Results
Printer Friendly Version 
January 28, 2014 - 5:01 p.m.
Gilead Sciences to Release Fourth Quarter and Year End 2013 Financial Results on Tuesday, February 4, 2014
Printer Friendly Version 
January 27, 2014 - 5:01 p.m.
Gilead Announces Executive Promotions
Printer Friendly Version 
January 17, 2014 - 9:10 a.m.
European Commission Grants Marketing Authorization for Gilead’s Sovaldi® (Sofosbuvir) for the Treatment of Chronic Hepatitis C Infection
Printer Friendly Version 
January 13, 2014 - 8:31 a.m.
U.S. FDA Accepts New Drug Application for Gilead’s Idelalisib for the Treatment of Refractory Indolent Non-Hodgkin’s Lymphoma
Printer Friendly Version 
January 10, 2014 - 5:01 p.m.
Gilead Sciences to Present at the 32nd Annual JPMorgan Healthcare Conference on Monday, January 13
Printer Friendly Version 
January 06, 2014 - 4:32 p.m.
Gilead Sciences’ Kevin Young CBE, Executive Vice President, Commercial Operations, to Retire
Printer Friendly Version 
NASDAQ (US Dollar)
$73.86
 Stock is Up 1.00 (1.37%)
Data as of 04/23/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh Quote